Key points from article :
RxCelerate announced the acquisition of Cambridge-based drug discovery company Methuselah Health UK.
“ProQuant can better quantify post-translational modifications, which opens up a new domain for target identification and validation, biomarker discovery and reaction monitoring,” - Jill Reckless, CEO at RxCelerate.
ProQuant has numerous applications across the drug discovery and development domains.
It turbo-charges chemoproteomics during discovery of covalent binders.
Allows the accumulation of post-translational modifications on biologic drugs to be accurately monitored.
“We have developed a toolkit of cutting-edge technologies to improve drug discovery and development,” - Nick Tait, Chief Financial Officer at RxCelerate.
“Galaxy, our platform to discover better monoclonal antibody drugs at RxBiologics, and RxNfinity," - Tait.
"With the acquisition, we have taken another step towards our vision of making the best technologies available to everyone," - Tait.
